Ensem Therapeutics To Present Preclinical Data for Potential Best-in-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader at San Antonio Breast Cancer Symposium

On December 1, 2024 Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble platform to advance innovative small molecule precision medicines for oncology, reported the first presentation of preclinical data on ETX-636, a potential best-in-class novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader (Press release, ENSEM Therapeutics, DEC 10, 2024, View Source [SID1234649019]). ETX-636 has a differentiated preclinical profile and the potential to deliver clinical benefit to patients with tumors harboring all forms of mutant PI3Kα. The ETX-636 preclinical data is being presented in a poster session during the 47th Annual San Antonio Breast Cancer Symposium ("SABCS") in San Antonio, Texas, on Dec. 12.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PI3Kα is among the most frequently mutated oncogenes, with activating mutations seen in approximately 16 percent of all tumors and up to 40 percent of hormone receptor positive/HER2-negative advanced breast cancer. However, wildtype PI3Kα is also central to glucose homeostasis and ATP-binding-site orthosteric inhibitors target both mutant and wildtype PI3Kα, resulting in hyperglycemia which limits the clinical utility of these therapeutics.

ETX-636 is a novel orally bioavailable allosteric pan-mutant-selective PI3Kα inhibitor and degrader. This dual mechanism of action results in deep and durable pathway inhibition and induces concordant tumor regression in kinase and helical domain PI3Kα-mutant breast cancer xenografts without inducing wildtype PI3Kα inhibition-mediated hyperglycemia or other toxicities. Additionally, in an ER-positive, HER2-negative, PI3Kα-mutant breast cancer xenograft, ETX-636 is efficacious as a single agent and shows synergistic activity with the standard-of-care agent fulvestrant. ENSEM believes this molecule will significantly improve outcomes for patients with PI3Kα mutations, whether in cancer or rare diseases.

"The promising preclinical results with ETX-636 underscore the potential of our Kinetic Ensemble platform to discover small molecules against high value and difficult to drug targets," said Shengfang Jin, CEO and Co-Founder of ENSEM. "Targeting mutant PI3Kα within tumors while sparing wildtype PI3Kα in normal tissues represents a significant clinical challenge. ETX-636 is a potent mutant-specific allosteric PI3Kα inhibitor and degrader which differentiates it from other compounds in its class." She noted that ETX-636 is completing IND-enabling studies with a first-in-human clinical trial anticipated in the first half of 2025. ENSEM will evaluate ETX-636 as a monotherapy and in combinations with standard-of-care agents in cancer patients harboring PI3Kα mutations.

Poster Details

Title: ETX-636, a Potential Best-In-Class, Oral Small Molecule Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader
Poster ID: P4-12-18
Sessions: Poster Session 4
Date/Time: Thursday, December 12, 2024, from 5:30 to 7 p.m. CT
Location: Halls 2-3

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

On December 10, 2024 Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma, reported an exclusive global license agreement to develop and commercialize NeraCare’s Immunoprint test on Akoya’s multiplexed immunofluorescent platform (Press release, Akoya Biosciences, DEC 10, 2024, View Source [SID1234648972]). Building on the research collaboration between the companies announced earlier this year, the license agreement grants Akoya the exclusive right to develop, market and commercialize the test for clinical research, diagnostic development or, following regulatory approval, patient clinical testing as both a laboratory test or a distributable diagnostic on Akoya’s PhenoImager HT platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Melanoma, the leading cause of skin cancer, sees over 235,000 new diagnoses every year, 80% of which are in early-stage disease (IA/IB/IIA). While these early-stage patients undergo surgery and subsequent monitoring, they are ineligible to receive effective adjuvant therapies approved for later stage melanoma. NeraCare’s Immunoprint assay addresses this critical unmet need by identifying early-stage melanoma patients at high risk of relapse, comparable to later-stage patients, making them ideally suited to potentially benefit from therapeutic options.

"The agreement builds on the complementary expertise of both companies: Akoya’s market-leading multiplex immunofluorescence technology and NeraCare’s innovative development and rigorous clinical validation of Immunoprint. Together, we aim to expand access to life-saving therapies for early-stage melanoma patients worldwide," said Friedrich Ackermann, Co-Founder of NeraCare.

"Our collaboration is a testament to the versatility of Akoya’s PhenoImager HT platform and the clinical impact spatial biology can deliver. Immunoprint has proven unparalleled in identifying high-risk melanoma patients through multiple clinical studies, and our partnership aims to offer a platform to address the unmet need for earlier therapeutic intervention," added Daniel von Janowski, Co-Founder of NeraCare.

"Our exclusive partnership with NeraCare for Immunoprint is a significant advancement of our clinical strategy providing Akoya and our pharmaceutical partners the opportunity to transform melanoma patient care We are honored to be partnering with NeraCare to help bring this test to market and serve a critical unmet need," said Brian McKelligon, CEO of Akoya Biosciences.

Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research

On December 10, 2024 Leapfrog Bio, a clinical-stage precision oncology company identifying novel therapies for undruggable cancer-driving mutations, reported that Tomas Babak, PhD, the Company’s Chief Scientific Officer, will present evidence that Leapfrog Bio’s Precision PGx Platform discovered a clinically significant link between the EP300 gene and bromodomain and extra-terminal domain (BET) protein inhibitors (Press release, Leapfrog Bio, DEC 10, 2024, View Source [SID1234648988]). The presentation titled, "EP300 loss of function is a pan-cancer sensitizer to BET inhibition," will take place at the AACR (Free AACR Whitepaper) Special Conference in Cancer Research in Toronto, Canada and will focus on the discovery, characterization and clinical development plan for Leapfrog Bio’s BET inhibitor LFB-190 to treat solid tumors with EP300 loss of function.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Loss of transcriptional control is a hallmark of cancer and can be an essential driver of cancer initiation and progression. BET proteins regulate the expression of multiple cancer-related genes and pathways; several molecules targeting this family of proteins have been tested in early phase clinical trials, although these molecules had shown limited clinical success as monotherapies. After conducting hundreds of pharmacogenetic screens using its Precision PGx Platform, Leapfrog Bio discovered an interaction between BET protein inhibition and the EP300 gene loss of function (LOF) similar to PARP-BRCA1/HRD in significance. The Company believes it has also discovered the mechanism of action for this synthetically lethal relationship between BET protein inhibition and EP300 LOF.

"It was gratifying to identify this essential interaction, as there has been so much research and activity related to BETs inhibitors," said Tomas Babak, PhD, CSO of Leapfrog Bio. "Discovering a strong interaction between BET proteins and the mutated EP300 gene resulting in LOF—as well as the mechanism that drives it—using the Precision PGx Platform is a meaningful validation of the platform’s ability to identify therapies for previously undruggable cancers caused by LOF mutations. Two-thirds of all cancers are caused by mutations in tumor suppressor genes, such as what we see here with EP300, yet less than one percent of LOF tumor suppressor genes have been drugged to date. With Leapfrog Bio’s platform, we can repeatedly uncover candidates that address the unmet needs of patients with cancers caused by LOF mutations."

Leapfrog’s Lead Candidate, LFB-190, exploits the relationship between BET inhibition and EP300 LOF mutations. The Company’s Phase 2-ready compound was clinically studied prior to Leapfrog’s research and a recommended Phase 2 dose has been established.

Greg Vontz, CEO of Leapfrog Bio added, "This discovery demonstrates the ability of the Precision PGx Platform to uncover potential therapeutic solutions for the 10M patients with cancers driven by LOF mutations. We have filed IP around this discovery and are currently preparing for LFB-190’s entry into Phase 2 in lung, colon and bladder cancers in 2025."

TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies

On December 10, 2024 TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases, reported the poster presentation at the 2024 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to discuss the phase I study results of TT-01488, a novel reversible BTK inhibitor for patients with relapsed or refractory B-cell malignancies (Press release, TransThera Biosciences, DEC 10, 2024, View Source;in-patients-with-relapsed-or-refractory-b-cell-malignancies-302326854.html [SID1234649004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bruton’s tyrosine kinase (BTK) plays a critical role in the B-cell receptor signaling pathway, functioning as an important regulator of cell proliferation and cell survival in various B-cell malignancies. Currently there are 5 approved irreversible BTK inhibitors (BTKis) in the world. Due to the emergence of acquired mutation in the inhibitor’s covalent binding site (C481S), there is a high unmet medical need to develop next-generation BTKi to overcome the resistance.

TT-01488 is a next-generation, non-covalent, reversible BTKi which can overcome the acquired resistance to irreversible BTKis. In the preclinical study, TT-01488 potently Inhibits both wildtype and C481S-mutant BTK.

The Phase I study of TT-01488 presented at ASH (Free ASH Whitepaper) Annual Meeting was an open, multi-center, dose escalation study. As of the data cut-off date on October 2, 2024, 18 patients with pre-treated B-cell malignancies were enrolled, with the median 3 lines of prior therapies. TT-01488 was well-tolerated in all patients. Neither dose limiting toxicity (DLT) occurred nor any bleeding, atrial flutter or atrial fibrillation was reported. In pharmacokinetics and pharmacodynamics study, sustained pBTK C481S-mutant inhibition covering IC­90 was observed at steady state following multiple dosing at both 150 mg (QD) and 100 mg (BID) dose levels. Among 14 efficacy evaluable patients, objective response rate (ORR) was 57% (8/14),including 3 complete remission (CR) and 5 partial remission (PR). 100% (7/7) of ORR was achieved in mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM) and marginal zone lymphoma (MZL). Overall, TT-01488 showed encouraging efficacy in B-cell non-Hodgkin lymphoma (B-NHL) patients, regardless of C481S status and with/without prior cBTKi therapy.

About TT-01488

TT-01488 is an internally developed, non-covalent, reversible BTK inhibitor to overcome acquired resistance developed from marketed covalent BTK inhibitors in various types of relapsed or refractory hematological malignancies. TT-01488 is highly potent against BTK wild type and mutation with high selectivity over EGFR and Tec, indicating its potential for good efficacy and safety.

Tempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

On December 10, 2024 Tempus, a leader in artificial intelligence and precision medicine, reported four abstracts were accepted for presentation at the 2024 San Antonio Breast Cancer Symposium, which convenes from December 10-13, in San Antonio, Texas (Press release, Tempus, DEC 10, 2024, View Source [SID1234649020]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Presenting our latest research at the San Antonio Breast Cancer Symposium underscores Tempus’ commitment to advancing precision medicine for breast cancer patients," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "By leveraging the power of real-world data and AI-driven insights, Tempus is dedicated to empowering clinicians with tools that can improve patient outcomes and accelerate the pace of research in breast cancer."

Highlights of this year’s Tempus presentations include:

Poster Spotlight Presentation (#PS19-02): Economic Impact of Concurrent Tissue and Circulating Tumor DNA Molecular Profiling In Advanced Breast Cancer Patients
Session Date & Time: Thursday, December 12, 2024; 5:30 – 7:00 p.m. CT
Location: Henry B. Gonzalez Convention Center, Hemisfair Ballroom 1-2

Overview: Compared to tissue testing alone, concurrent solid tissue and circulating tumor DNA (ctDNA) testing identified an additional 20% of patients with actionable findings, reducing the need for repeat biopsies and associated adverse events. In a simulated cohort, concurrent testing detected 92 more patients with actionable variants compared to tissue testing alone and prevented 24 additional biopsies at an incremental cost of $2,715 per patient—less than the cost of an extra liquid biopsy. The approach demonstrates an approach for enhancing patient care by improving diagnostic yield and decreasing the number of unnecessary procedures at an incremental cost that is less than the cost of a liquid biopsy.

Poster Presentation (#P1-03-25): Characterization of the tumor immune microenvironment (TIME) and somatic landscape of metaplastic breast cancer (MpBC)
Session Date & Time: Wednesday, December 11, 2024; 12:30 – 2:00 p.m. CT
Location: Henry B. Gonzalez Convention Center, Halls 2 & 3

Overview: A retrospective analysis from the Tempus database revealed that patients with Metaplastic breast cancer (MpBC), a rare, aggressive subtype with a dismal prognosis, had a distinct molecular phenotype compared to non-MpBC. In patients with MpBC, there was a higher prevalence of triple-negative breast cancer (TNBC), and a distinct somatic alteration profile. Somatic alterations in TERT, CDKN2A/B, MTAP and genes involved in the PI3k pathway were more common in MpBC, compared to non-MpBC patients, providing insights into potential therapeutic targets. The study also found a unique tumor immune microenvironment in MpBC, primarily characterized by a higher PD-L1 expression. These analyses provide further rationale to develop new biomarker-selected treatment strategies in a subtype that is challenging to treat and under-represented in trials.

Poster Presentation (#P2-09-21): Low-level Aurora kinase A (AURKA) amplification as a novel personalized biomarker of CDK4/6 inhibitor resistance in patients with hormone-receptor positive (HR+) metastatic breast cancer
Session Date & Time: Wednesday, December 11, 2024; 5:30 – 7:00 p.m. CT
Location: Henry B. Gonzalez Convention Center, Halls 2 & 3

Overview: In a study of patients with HR+/HER2- metastatic breast cancer (HR+ MBC), low-level AURKA copy number gains were found to be common and associated with resistance to CDK4/6 inhibitors (CDK4/6i). The Tempus database was used to analyze genomic records from tumors sequenced with the Tempus xT DNA seq and xR RNA seq assays, revealing that 15% of patients had AURKA amplifications, which are not typically reported by standard sequencing platforms. Findings showed that patients with AURKA amplifications had significantly shorter progression-free survival (9.9 months) on CDK4/6i compared to those without (17 months), suggesting that AURKA amplification is a potential marker of CDK4/6i resistance. This research underscores the importance of identifying low-level AURKA gains, as they could inform more personalized use of emerging AURKA-targeted therapies like alisertib and further studies are needed.